Alzheimer’s Disease & the Endocannabinoid System



A lot of parallels exist among cannabis and psychedelics. Amongst them are the varied therapeutic consequences for which equally courses of drugs are now being investigated, from combating pain and inflammation to aiding cure of some psychiatric issues. Also on the record: Alzheimer’s Ailment, the most popular neurodegenerative illness with as many as 6.2 million People in america living with the problem. (The up coming most widespread is Parkinson’s Illness at 1.2 million.)

Cannabinoids could be good candidates for treating Alzheimer’s Disease.

On the psychedelic front, a review report published very last 12 months in the journal Frontiers in Synaptic Neuroscience1 makes a solid situation for LSD and psilocybin as opportunity solutions for this progressively disabling issue. A analyze now underway at Johns Hopkins University’s Centre for Psychedelic and Consciousness Research and an additional posted in 20192 by psychedelic medication enterprise Eleusis sign critical interest in Alzheimer’s among the the field’s weighty hitters.

And in the planet of hashish science, the plant has been analyzed as a probable cure for Alzheimer’s Condition given that at least the change of the century. These days interest in the subject is increased than at any time. The scientific publisher Frontiers lately issued a call for papers on “targeting the endocannabinoidome in neurodegenerative disorders,” recognizing the issue as a “hot study location.” (The time period “endocannabinoidome” refers to the expanded endocannabinoid technique, such as supplemental mediators, enzymes, and molecular targets.)

In September 2021 on your own, three papers appeared in the scientific literature summarizing much of what is acknowledged about Alzheimer’s Disease and the endocannabinoid process.

CBD for Alzheimer’s Sickness

An posting posted in the journal Brain Sciences3 reviews how the endocannabinoid process (ECS) may be concerned in the progress of Alzheimer’s Disorder – and how cannabidiol (CBD) and other cannabinoids may well be used to support deal with it. The discussion gets fairly complex, but here are the authors’ highlights of what the science from the previous couple a long time implies:

  • Postmortem assessment has uncovered adjustments to quite a few factors of the ECS in the brains of Alzheimer’s people. Expression of CB1 cannabinoid receptors is lowered, even though expression of CB2 receptors is markedly improved in the frontal or parahippocampal cortex, “probably in a time-dependent way.”
  • Elevated expression of CB2 receptors is pronounced in and all-around amyloid plaques (aggregates of abnormally configured proteins that are deemed a hallmark of Alzheimer’s Ailment and cognitive decrease), indicating a correlation involving the ECS and plaque deposition.
  • Expression of the enzymes FAAH [fatty acid amide hydrolase] and MAGL [monoacylglycerol lipase] – which metabolize the endocannabinoids anandamide and 2-Arachidonoylglycerol (2-AG) , respectively – boosts in the brains of Alzheimer’s people. So also does expression of a 3rd essential enzyme, DAGL [diacylglycerol lipase], which synthesizes 2-AG.
  • Provided the modulatory outcomes of cannabinoids on the ECS, cannabinoids may well be superior candidates for managing Alzheimer’s Disease. Scientific trials have already noted that cannabinoids may be beneficial for reducing some symptoms in people with Alzheimer’s or dementia.

Though both THC and CBD offer assure in this regard and are known to be neuroprotective, “the concomitant psychotropic effects of THC pose a problem,” the authors produce. (THC’s intoxicating outcomes are mediated by CB1, though the compound also binds to CB2 CBD does not have a strong affinity for either.) As a result, CBD has attracted growing notice for its therapeutic probable.

Focusing on Cannabinoid Receptor 2 to Treat Dementia

A next the latest evaluation, posted in the Journal of Neuroscience Study4 in early September, takes a somewhat distinctive tack. Instead of concentrating on plant cannabinoids, it attracts on lots of of the identical things linking the ECS with Alzheimer’s Sickness to make a case for selectively focusing on CB2 (which does not mediate psychotropic results) when building novel medication to handle Alzheimer’s and connected conditions.

“In the treatment of neurodegenerative diseases, CB2 agonists have demonstrated promising effects,” the India-primarily based authors generate. (An “agonist” activates a receptor and leads to it to signal, while an antagonist blocks the receptor.) “The experimental proof indicates that they could be helpful in the administration of Alzheimer’s Disorder by lowering swelling, tau hyperphosphorylation, beta-amyloid aggregation, [and] oxidative tension, and increasing cognitive purpose.”

The paper cites a lot of examples of selective CB2 agonists made and analyzed for dealing with soreness, arthritis, irritation, and other disorders by organizations together with GlaxoSmithKline, Glenmark Prescription drugs, Corbus Prescribed drugs, and Eli Lilly. Hence significantly, however, professional medical experts have not been able to translate early-section clinical trials involving CB2 agonists into practical, clinically successful prescribed drugs.

Alzheimer’s & Gut Microbiota

In modern yrs the intestine microbiome has emerged as a intriguing player in human wellness and illness. Disturbances to this program have been linked with a wide range of adverse outcomes like obesity, most cancers, and (you guessed it) neurodegenerative ailments these types of as Alzheimer’s and Parkinson’s.

A lot less frequently resolved in popular accounts of the intestine microbiome are its interactions with the endocannabinoid system. As Challenge CBD explained in a 2020 article, the ECS serves as a form of bridge among resident bacteria and the human body by itself, which include the brain, by relaying indicators back again and forth inside this symbiotic, mutually advantageous romantic relationship.

In a recent review in the journal Everyday living5 , a group of Italian scientists employs this same metaphor to conceptualize how the ECS may be key to mediating the connection between intestine flora dysbiosis and Alzheimer’s physiopathology. The two interacting systems may serve as “common denominators” in the illness, the scientists advise. “The overlapping roles of the encodcannabinoid system and the microbiome…suggest that a novel method this kind of as modulating the microbiota via [the ECS] may deliver new therapeutic perspectives for dealing with Advert,” they conclude.

​Nate Seltenrich, an unbiased science journalist dependent in the San Francisco Bay Area, handles a large assortment of topics together with environmental well being, neuroscience, and pharmacology.

Copyright, Job CBD. May perhaps not be reprinted without the need of permission.

Footnotes